Corvus Pharmaceuticals (CRVS) Equity Income (2021 - 2023)

Corvus Pharmaceuticals' Equity Income history runs 3 years deep, the most recent figure standing at -$1.4 million for Q4 2023.

• On a quarterly basis, Equity Income rose 69.73% year-over-year to -$1.4 million in Q4 2023; TTM through Dec 2023 was -$5.3 million, a 47.19% increase from a year earlier, with the FY2023 full-year figure at -$5.3 million, up 47.19% from the prior year.
• Equity Income eased to -$1.4 million in Q4 2023 per CRVS's latest filing, from -$865000.0 in the prior quarter.
• Across five years, Equity Income topped out at -$100000.0 in Q1 2021 and bottomed at -$4.6 million in Q4 2022.
• The 3-year median for Equity Income is -$1.5 million (2022), against an average of -$1.7 million.
• Across the five-year window, Equity Income sank 941.0% in 2022 and soared 69.73% in 2023, its largest moves.
• Year by year, Equity Income stood at -$2.6 million in 2021, then slumped by 81.24% to -$4.6 million in 2022, then surged by 69.73% to -$1.4 million in 2023.
• Per Business Quant, the three latest CRVS Equity Income figures stand at -$1.4 million (Q4 2023), -$865000.0 (Q3 2023), and -$1.3 million (Q2 2023).